Passage Bio (PASG) Financials: Revenue & Earnings

PASG price $3.31 -0.04 -1.33%

Ticker
PASG
Price
$3.31
Change
-0.04 -1.33%
Market cap ?
$10.64M
P/E ?
-0.30
Dividend yield ?
0.00%
Beta ?
1.39
Sector
Healthcare
Industry
Biotechnology

Financials

20182019202020212022202320242025
00000000

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues…

Fair value

PASG fair value Not meaningful. Price $3.31.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Not meaningful

Compare PASG

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-09—-2.43——
2026-08-10-2.44-2.27——
2026-05-12-2.36-2.15——
2026-03-03-4.08-2.19——
2025-11-10-2.44-2.76——
2025-08-12-2.96-4.00——
2025-05-13-5.00-4.60——
2025-03-04-4.00-0.23——
2024-11-13-6.20-4.60—1.67M
2024-08-08-5.20-6.20——
2024-05-13-6.00-0.37——
2024-03-04-6.00-0.41——
2023-11-13-9.80-0.47——
2023-08-07-8.80-0.48——
2023-05-11-12.00-0.54——
2023-03-06-0.50-0.48——
2022-11-10-0.49-0.78——
2022-08-04-0.73-0.83——
2022-05-16-15.80-0.89——
2022-03-03-18.60-0.89——
2021-11-04-15.40-16.00——
2021-08-05-18.00-14.60——
2021-05-05-15.20-13.20——
2021-03-03-17.00-13.80——
2020-11-10-12.60-14.60——
2020-08-13-12.00-12.00——
2020-05-11-20.00-9.20——
2020-02-28-11.00———
2019-06-30-0.56———
2019-03-31-0.32———
2018-12-31-1.47———

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-06-25Lynx1 Capital Management LPBuy50.05K$4.12206.10K
2026-05-19Sondhi DolanBuy10.54K$5.0853.54K
2026-05-19Porter DerrellBuy10.54K$5.0853.54K
2026-05-19Kassberg Thomas RichardBuy10.54K$5.0853.54K
2026-05-19Kapadia SandipBuy10.54K$5.0853.54K
2026-05-19GOWEN MAXINEBuy10.54K$5.0853.54K
2026-05-19Countouriotis AthenaBuy10.54K$5.0853.54K
2026-03-16Borthwick KathleenBuy15.61K$7.64119.26K
2026-03-16Chou WilliamBuy58.00K$7.64443.12K
2026-01-08Chou WilliamBuy10.00K——
2026-01-08Chou WilliamSell10.00K——
2026-01-08Chou WilliamSell4.08K$18.4475.16K
2026-01-08Borthwick KathleenBuy5.00K——
2026-01-08Borthwick KathleenSell2.06K$18.4438.02K
2026-01-08Borthwick KathleenSell5.00K——
2025-09-15Lynx1 Capital Management LPBuy11.90K$6.9983.18K
2025-09-12Lynx1 Capital Management LPBuy19.78K$6.99138.30K
2025-09-11Lynx1 Capital Management LPBuy325$6.962.26K
2025-07-24Lynx1 Capital Management LPBuy66.42K$5.71379.45K
2025-07-23Lynx1 Capital Management LPBuy49.30K$5.74283.03K
2025-07-22Lynx1 Capital Management LPBuy13.12K$5.4471.34K
2025-06-26ORBIMED ADVISORS LLCSell213.26K$0.3370.37K
2025-06-25ORBIMED ADVISORS LLCSell138.80K$0.3345.80K
2025-06-24ORBIMED ADVISORS LLCSell231.60K$0.3581.06K
2025-05-28Kapadia SandipBuy201.86K$0.3672.63K
2025-05-28GOWEN MAXINEBuy201.86K$0.3672.63K
2025-05-28Countouriotis AthenaBuy201.86K$0.3672.63K
2025-05-28Porter DerrellBuy201.86K$0.3672.63K
2025-05-28Islam SaqibBuy201.86K$0.3672.63K
2025-05-28Sondhi DolanBuy201.86K$0.3672.63K
2025-05-28Kassberg Thomas RichardBuy143.79K$0.3651.74K
2025-04-24ORBIMED ADVISORS LLCSell68.19K$0.3221.82K
2025-04-23ORBIMED ADVISORS LLCSell89.33K$0.3430.37K
2025-04-22ORBIMED ADVISORS LLCSell78.05K$0.3426.54K
2025-04-17ORBIMED ADVISORS LLCSell77.09K$0.3325.44K
2025-04-16ORBIMED ADVISORS LLCSell61.64K$0.3320.34K
2025-04-15ORBIMED ADVISORS LLCSell10.33K$0.383.92K
2025-03-15Borthwick KathleenBuy278.39K$0.39107.74K
2025-03-15Chou WilliamBuy779.53K$0.39301.68K
2025-03-15Cale Edgar B.Buy278.39K$0.39107.74K
2025-02-11Borthwick KathleenSell3.18K$0.531.69K
2025-02-10Borthwick KathleenBuy8.00K——
2025-02-10Borthwick KathleenSell8.00K——
2025-01-15Borthwick KathleenBuy10.00K——
2025-01-15Chou WilliamBuy20.00K——
2025-01-14ORBIMED ADVISORS LLCSell79.02K$0.6047.41K
2025-01-13ORBIMED ADVISORS LLCSell17.99K$0.6411.51K
2025-01-10ORBIMED ADVISORS LLCSell126.21K$0.6683.30K
2025-01-08ORBIMED ADVISORS LLCSell75.01K$0.6851.00K
2025-01-07ORBIMED ADVISORS LLCSell52.54K$0.7137.30K
2025-01-06ORBIMED ADVISORS LLCSell19.48K$0.7715.00K
2024-12-27Lynx1 Capital Management LPBuy373.64K$0.65241.04K
2024-12-20ORBIMED ADVISORS LLCSell230.32K$0.60138.19K
2024-12-11ORBIMED ADVISORS LLCSell80$0.8064
2024-12-10ORBIMED ADVISORS LLCSell8.02K$0.806.41K
2024-12-09ORBIMED ADVISORS LLCSell54.18K$0.8445.51K
2024-12-06ORBIMED ADVISORS LLCSell20.90K$0.8217.14K
2024-12-04ORBIMED ADVISORS LLCSell76.20K$0.7960.20K
2024-11-27Lynx1 Capital Management LPBuy29.30K$0.6719.66K
2024-11-26Lynx1 Capital Management LPBuy167.06K$0.71118.19K
2024-11-25Lynx1 Capital Management LPBuy260.00K$0.56146.66K
2024-09-30Cale Edgar B.Buy50.00K$0.7035.00K
2024-09-30Kassberg Thomas RichardBuy174.14K$0.70121.90K
2024-09-19ORBIMED ADVISORS LLCSell39.30K$0.7127.90K
2024-09-18ORBIMED ADVISORS LLCSell25.63K$0.7318.71K
2024-09-17ORBIMED ADVISORS LLCSell111.40K$0.7381.32K
2024-09-16ORBIMED ADVISORS LLCSell63.10K$0.7446.69K
2024-09-10Kassberg Thomas RichardOther0——
2024-08-07Lynx1 Capital Management LPOther0——
2024-05-21Countouriotis AthenaBuy47.69K$1.2861.05K
2024-05-21GOWEN MAXINEBuy47.69K$1.2861.05K
2024-05-21Kapadia SandipBuy47.69K$1.2861.05K
2024-05-21Islam SaqibBuy47.69K$1.2861.05K
2024-05-21Sondhi DolanBuy39.09K$1.2850.04K
2024-05-21Porter DerrellBuy47.69K$1.2861.05K
2024-03-15Borthwick KathleenBuy227.00K$1.50340.50K
2024-03-15Forman Mark SBuy203.00K$1.50304.50K
2024-03-15Chou WilliamBuy575.00K$1.50862.50K
2024-03-15Cale Edgar B.Buy203.00K$1.50304.50K
2024-02-13Borthwick KathleenSell1.47K$0.971.43K
2024-02-13Forman Mark SSell1.64K$0.971.59K
2024-02-10Borthwick KathleenBuy4.00K——
2024-02-10Borthwick KathleenSell4.00K——
2024-02-10Forman Mark SBuy5.00K——
2024-02-10Forman Mark SSell5.00K——
2024-01-02Forman Mark SSell15.81K$0.9114.39K
2024-01-02Borthwick KathleenSell10.67K$0.919.71K
2024-01-02Cale Edgar B.Sell15.81K$0.9114.39K
2023-12-31Forman Mark SBuy50.00K——
2023-12-31Forman Mark SSell50.00K——
2023-12-31Borthwick KathleenBuy30.00K——
2023-12-31Borthwick KathleenSell30.00K——
2023-12-31Cale Edgar B.Buy50.00K——
2023-12-31Cale Edgar B.Sell50.00K——
2023-07-28King SimonaBuy31.25K——
2023-07-28King SimonaSell11.45K$0.8810.08K
2023-07-28King SimonaSell31.25K——
2023-07-28Sondhi DolanOther0——
2023-07-28Borthwick KathleenBuy20.00K$0.8817.55K
2023-07-28Borthwick KathleenSell56.00K$6.75378.00K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 29, holders -4 vs prior quarter. Ownership 133.52%.

HolderSharesChangeChange %Value
CITADEL ADVISORS LLC2.89M2.89MNew4.31M
LYNX1 CAPITAL MANAGEMENT LP673.76K50.05K+8.03%3.29M
VANGUARD CAPITAL MANAGEMENT LLC113.96K00.00%556.14K
BALYASNY ASSET MANAGEMENT L.P.107.03K107.03KNew522.28K
IKARIAN CAPITAL, LLC99.52K31.39K+46.08%485.64K
YIHENG CAPITAL MANAGEMENT, L.P.86.10K00.00%420.15K
RENAISSANCE TECHNOLOGIES LLC47.89K-85.72K-64.16%233.71K
ERSTE ASSET MANAGEMENT GMBH40.66K-44.60K-52.31%197.22K
GEODE CAPITAL MANAGEMENT, LLC37.03K-4.35K-10.52%180.72K
VERDAD ADVISERS, LP30.73K8.60K+38.86%149.95K
BOOTHBAY FUND MANAGEMENT, LLC28.44K9.57K+50.70%138.78K
BLACKROCK, INC.27.91K-685-2.40%136.20K
ACADIAN ASSET MANAGEMENT LLC22.50K-1.70K-7.03%109.00K
VANGUARD FIDUCIARY TRUST CO17.05K00.00%83.20K
DELTEC ASSET MANAGEMENT LLC15.00K15.00KNew73.20K
UBS GROUP AG13.56K-13.94K-50.67%66.20K
HRT FINANCIAL LP12.71K12.71KNew62.00K
FIDUCIARY TRUST CO10.75K00.00%52.46K
GTS SECURITIES LLC10.00K10.00KNew48.80K
MORGAN STANLEY2.39K-261-9.85%11.66K
VANGUARD GLOBAL ADVISERS, LLC63800.00%3.11K
BARCLAYS PLC21200.00%1.03K
SBI SECURITIES CO., LTD.16945+36.29%825
WELLS FARGO & COMPANY/MN11500.00%561
OSAIC HOLDINGS, INC.1500.00%73

Earnings and financials

Passage Bio, Inc. (PASG) trades at $3.31, with a market cap of $10.64M and a trailing P/E of -0.30. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

20182019202020212022202320242025
00000000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Passage Bio (PASG) Financials: Revenue & Earnings

PASG$3.31-0.04 -1.33%

$10.64M

Market Cap

-0.30

P/E

—

Forward P/E

—

Score

Price History